4.1 Review

Silymarin for HCV infection

期刊

ANTIVIRAL THERAPY
卷 18, 期 2, 页码 141-147

出版社

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP2402

关键词

-

资金

  1. NIH [R01AT006842, R56/R01-AI078881, P20-GM103452]
  2. US Department of Energy
  3. Agence Nationale pour la Recherche contre le SIDA et les hepatites virales (ANRS)
  4. ANRS
  5. INSERM
  6. Fondation pour la Recherche Medicale
  7. National Center for Complementary & Integrative Health [R01AT006842] Funding Source: NIH RePORTER
  8. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078881, R56AI078881] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103452] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Silymarin, an extract of milk thistle seeds, and silymarinderived compounds have been considered hepatoprotective since the plant was first described in ancient times. Hepatoprotection is defined as several non-mutually exclusive biological activities including antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for beneficial effects in humans has been equivocal. This review will summarize the current state of knowledge on silymarin in the context of HCV infection. The information was collated from a recent workshop on silibinin in Germany.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据